Mankind Pharma Limited recorded a substantial block trade on the National Stock Exchange (NSE), highlighting significant institutional activity in the pharmaceutical company's shares. The transaction represents one of the notable trading activities in the healthcare sector.

Block Trade Details

The block trade executed on NSE involved considerable value and volume, demonstrating strong institutional interest in Mankind Pharma's stock.

Market Significance

Block trades typically occur when institutional investors, including mutual funds, insurance companies, pension funds, or foreign institutional investors, execute large transactions. These trades are conducted separately from the regular market to avoid significant price impact on the stock during normal trading hours.

The transaction price of ₹2,156.60 per share reflects the market valuation at which institutional participants were willing to transact in Mankind Pharma shares. Such block deals often indicate confidence from large investors in the company's prospects or portfolio rebalancing activities by institutional funds.

Trading Activity Impact

The substantial volume of 243,821 shares changing hands in a single block transaction represents significant liquidity in Mankind Pharma stock. Block trades of this magnitude typically suggest strong institutional participation and can influence overall trading sentiment in the stock.

This block trade activity demonstrates the continued institutional interest in India's pharmaceutical sector, with Mankind Pharma being a key participant in the domestic pharmaceutical market.

Mankind Pharma Limited has informed stock exchanges about receiving a significant GST penalty order from tax authorities, though the company maintains it will contest the decision through appropriate legal channels.

GST Order Details

The pharmaceutical company received an order on December 10, 2025, from the Office of the Principal Commissioner, Central GST Central Excise, Patna, issued by the Joint Commissioner under applicable provisions of the GST Act. The order spans five financial years and carries substantial monetary implications.

Nature of Violation

The GST order pertains to disallowance of Input Tax Credit (ITC) on account of reconciliation differences in the GST returns filed by the company. This relates to discrepancies identified by the Bihar GST Authority under the Central Goods and Services Tax Act, 2017.

Company's Response and Legal Position

Mankind Pharma has expressed confidence in its legal standing regarding the matter. The company stated it possesses adequate factual and legal grounds to substantiate its position and considers the order not tenable in law.

Key aspects of the company's response include:

• Plans to file necessary appeal with the appellate authority
• Assessment that the order lacks legal foundation
• Confidence in factual and legal grounds supporting their position
• Commitment to taking appropriate legal action

Financial and Operational Impact

The company has assessed the potential impact of this GST order on its business operations and financial performance. Based on their evaluation of facts and prevailing law, Mankind Pharma expects no material impact on its financials, operations, or other activities.

Regulatory Compliance

This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders regarding material developments. The company has provided detailed information as required under the regulatory framework, including the SEBI Master Circular dated November 11, 2024.

The matter represents a routine regulatory challenge that pharmaceutical companies may face regarding GST compliance, and Mankind Pharma appears prepared to address it through established legal procedures.